|

REGN5678 Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: Nezastomig, PYLARIFY

Pipeline

Phase 1: 1Phase 1/2: 3

Top Sponsors

  • Regeneron Pharmaceuticals2
  • M.D. Anderson Cancer Center2

Indications

  • Cancer4
  • Prostate Cancer2
  • Radical Prostatectomy1
  • Clear Cell Renal Cell Carcinoma (ccRCC)1
  • Metastatic Castration-resistant Prostate Cancer, mCRPC1

Houston, Texas2 trials

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

The University of Texas M. D. Anderson Cancer Center

Phase 1
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

M D Anderson Cancer Center

Phase 1/2

Gilbert, Arizona1 trial

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Banner MD Anderson Cancer Center

Phase 1/2

Palo Alto, California1 trial

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Stanford University Medical Center - Blake Wilbur Drive

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.